Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 14/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 11/20 | 1.00 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5727788 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3TBXA2R | |
| SCHEMBL4944499 | 1.00 | PTGER4 (1.00) | PTGER4PTGER2PTGER3TBXA2R | |
| SCHEMBL4942030 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL13817746 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4942164 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4942153 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4942045 | 0.90 | PTGER4 (1.00) | PTGER4PTGER2PTGER3 | |
| SCHEMBL4939001 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2PTGER3TBXA2R | |
| SCHEMBL4939006 | 0.90 | PTGER4 (0.81) | PTGER4PTGER2PTGER3TBXA2R | |
| SCHEMBL4942403 | 0.89 | PTGER4 (0.81) | PTGER4PTGER2PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | claimed |
| US-7419999-B2 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-09-02 | — | — | US | disclosed |
| EP-1556347-A4 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS (AN) | 2006-08-09 | — | — | EP | disclosed |
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-12-29 | — | — | US | disclosed |
| EP-1556347-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2005-07-27 | — | — | EP | disclosed |
| WO-2003103604-A2 | GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V (AN) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288357-A1 | Gamma lactams as prostaglandin agonists and use thereof | PGF, HPGDS, PTGIS | PTGER4 11/4885PTGER2 8/4885PTGER3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.